Bibliography
- Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
- Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis:What are the targets for therapy J Neurol Sci 2010. [Epub ahead of print]
- Mangas A, Covenas R, Geffard M. New drug therapies for multiple sclerosis. Curr Opin Neurol 2010;23:287-92
- Compston A, Confavreux C, McDonald I, McAlpine's Multiple sclerosis. 4th edition Churchill Livingstone Elsevier; Edinburgh 2006
- Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to understand multiple sclerosis. Nat Rev Immunol 2009;9:408-17
- Noseworthy JH, Wolinsky JS, Lublin FD, Linomide in relapsing and secondary progressive MS. Part I: trial design and clinical results. Neurology 2000;54:1726-33
- Wolinsky JS, Narayana PA, Noseworthy JH, Linomide in relapsing and secondary progressive MS. Part II: MRI results, MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide investigators. Neurology 2000;54:1734-41
- Jonsson S, Andersson G, Fex T, Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders-activity relationship. J Med Chem 2004;47:2075-88
- Polman C, Barkhof F, Sandberg-Wollheim M, Laquinimod in relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91
- Comi G, Pulizzi A, Rovaris M, Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92
- Comi G, Abramsky A, Arbizu T, for the LAQ/5063 Study Group. Oral laquinimod in patients with relapsing–remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Multiple Sclerosis 2010;16:1360-6
- Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Exp Opin Investig Drugs 2009;18:985-9
- Tuvesson H, Hallin I, Persson R, Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005;33:866-72
- Brunmark C, Runstrom A, Ohlsson L, The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;30:163-72
- Yang JS, Xu LY, Xiao BG, Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3-9
- Wegner C, Stadelmann C, Pfortner, Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demylination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-43
- Zou LP, Abbas N, Volkmann I, Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacol 2002;42:731-9
- Gurevich M, Gritzman T, Orbach R, Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol 2010;221:87-94
- Thone J, Seubert S, Conrad R, Laquinimod induces up-regulation of BDNF in serum of patients with relapsing-remitting multiple sclerosis. Am Acad Neurol 2010;74(Suppl 2):A405
- Thone J, Lee DH, Seubert S, Laquinimod ameliorates experimental autoimmune encephalomyelitis via BDNF dependent mechanism. Multiple Sclerosis, 2010;16:P881